Morgan Stanley Downgrades Vigil Neuroscience to Underweight, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has downgraded Vigil Neuroscience (NASDAQ:VIGL) from Equal-Weight to Underweight and reduced the price target from $13 to $4.
December 19, 2023 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley downgraded Vigil Neuroscience to Underweight and significantly lowered the price target from $13 to $4, indicating a bearish outlook.
The downgrade by a major analyst like Morgan Stanley can have a significant negative impact on investor sentiment and the stock price of Vigil Neuroscience in the short term. The substantial reduction in the price target suggests that the analyst sees considerable downside risk to the stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100